Updated: February 22, 2026
How to Help Your Patients Find Zavzpret in Stock: A Provider's Guide
Author
Peter Daggett

Summarize with AI
A practical guide for providers on helping patients locate and fill Zavzpret prescriptions. Includes workflow tips, alternatives, and access tools.
Your Patients Need Zavzpret — Here's How to Help Them Get It
You've determined that Zavzpret (Zavegepant) is the right treatment for your patient's acute migraines. The intranasal delivery avoids the GI absorption issues that plague many migraine patients, and the CGRP mechanism sidesteps the cardiovascular contraindications of triptans. It's the right clinical call.
But the prescription alone isn't enough. Your patient is likely going to face access challenges — from limited pharmacy stocking to insurance hurdles. This guide gives you a concrete, actionable workflow to maximize the likelihood that your patients actually receive their Zavzpret.
Current Availability: What to Expect
As of 2026, Zavzpret is not in a formal shortage. Pfizer's supply chain is intact. The challenge is at the retail pharmacy level:
- Many chain pharmacies do not routinely stock Zavzpret due to its high cost ($800–$1,100 per pack of 8 devices) and relatively low volume per location
- Independent pharmacies are variable but often more responsive to special orders
- Specialty and mail-order pharmacies are generally the most reliable channels
The key insight: the medication exists in the supply chain — the challenge is connecting your patient to the right pharmacy.
Why Patients Can't Find Zavzpret
Understanding the barriers helps you address them proactively:
Cost-Driven Stocking Decisions
At $800–$1,100 per pack, Zavzpret represents significant shelf investment for pharmacies. Unlike high-volume generics, the demand at any individual pharmacy location may not justify routine stocking. This is standard for newer specialty brands.
Insurance Prior Authorization Delays
The majority of payers require prior authorization for Zavzpret. Many also require step therapy documentation (typically a triptan trial and failure). When the PA isn't in place before the patient arrives at the pharmacy, the fill is rejected, and the patient leaves empty-handed.
Specialty Pharmacy Requirements
Some insurance plans mandate that Zavzpret be dispensed through specific specialty pharmacy networks. Patients may not learn about this requirement until their retail pharmacy attempts to process the claim.
Patient Awareness
Many patients don't know that they can request a special order, transfer prescriptions, or use tools to check pharmacy inventory. They may assume that if their pharmacy doesn't have it, it's unavailable.
What Providers Can Do: 5 Practical Steps
Step 1: Check Pharmacy Availability Before Prescribing
Use Medfinder for Providers to check which pharmacies in your patient's area currently have Zavzpret in stock. This takes seconds and prevents the most common failure point: sending a prescription to a pharmacy that doesn't carry it.
If the patient's preferred pharmacy doesn't stock Zavzpret, you can direct the prescription to one that does — or advise the patient to call ahead for a special order.
Step 2: Submit Prior Authorization Proactively
Don't wait for the pharmacy rejection to trigger the PA process. If you know the patient's plan requires prior authorization for Zavzpret (and most do), submit it at the time of prescribing. Include:
- Documented diagnosis of migraine
- Any prior triptan use and reasons for failure or contraindication
- Clinical rationale for intranasal delivery (e.g., significant nausea, vomiting during attacks)
- Any relevant comorbidities that preclude triptan use
Having the PA approved before the patient visits the pharmacy dramatically increases first-fill success rates.
Step 3: Provide Savings Program Information in the Exam Room
Cost is a major barrier for patients. Address it before they leave your office:
- Pfizer Savings Card: Commercially insured patients may qualify to pay as little as $0 per fill. The application can be started during the visit.
- Pfizer RxPathways: For uninsured or underinsured patients; may provide Zavzpret at no cost if income criteria are met.
Handing the patient a savings card or pointing them to Medfinder's savings guide ensures they don't abandon the prescription due to sticker shock at the pharmacy counter.
Step 4: Identify the Right Pharmacy Channel
Before sending the prescription, determine the optimal pharmacy channel:
- Retail pharmacy: Fine if the location stocks Zavzpret or the patient is willing to wait for a special order (1-3 days)
- Specialty pharmacy: Required by some plans; generally reliable but requires enrollment
- Mail-order pharmacy: Good for ongoing refills; initial fill may take longer
If the plan requires specialty pharmacy dispensing, help the patient initiate enrollment at the point of prescribing. Your staff can often start this process with a phone call.
Step 5: Follow Up on First Fill
A brief follow-up — even a quick message through your patient portal — to confirm the patient was able to fill the prescription can catch access problems before they escalate. If the first fill fails, you can troubleshoot immediately rather than learning about it weeks later at a follow-up visit.
Alternatives When Zavzpret Isn't Accessible
If access barriers prove insurmountable for a particular patient, these alternatives offer similar therapeutic benefit:
- Ubrelvy (Ubrogepant) 50 mg or 100 mg: Oral CGRP antagonist; same mechanism, different route. Good option when nausea isn't the primary concern.
- Nurtec ODT (Rimegepant) 75 mg: Orally disintegrating CGRP antagonist; dual indication for acute and preventive use. The ODT format helps with nausea-related compliance.
- Sumatriptan nasal spray 20 mg: Generic available; significantly more affordable. Contraindicated in cardiovascular disease.
- Trudhesa (Dihydroergotamine) nasal spray: Alternative intranasal option; ergot class; cardiovascular contraindications apply.
See the patient alternatives guide for comparisons you can share.
Workflow Tips for Your Practice
Integrating Zavzpret access management into your practice workflow doesn't have to be burdensome. Here are efficient approaches:
- Create a "Zavzpret prescribing checklist" for your staff: verify insurance coverage, submit PA, check pharmacy inventory, provide savings card information
- Designate 1-2 "go-to" pharmacies in your area that reliably stock Zavzpret and direct prescriptions there by default
- Use Medfinder for Providers as part of your prescribing workflow to check real-time availability
- Document step therapy failures thoroughly in the chart — this supports PA submissions and appeals
- Keep manufacturer support materials (savings card applications, RxPathways information) accessible in exam rooms
Final Thoughts
Zavzpret is a clinically valuable medication that fills a real gap in acute migraine treatment. The access challenges are real but predictable, and a proactive approach at the point of prescribing can resolve most of them.
By checking pharmacy availability, submitting prior authorizations early, connecting patients with savings programs, and choosing the right pharmacy channel, you can significantly improve your patients' experience and ensure they actually receive the treatment you've prescribed.
For the latest on Zavzpret availability, see our provider shortage briefing. And to check real-time pharmacy inventory, visit Medfinder for Providers.
Frequently Asked Questions
Specialty pharmacies and mail-order pharmacies generally offer the most consistent access to Zavzpret. For retail, identify specific locations that stock it regularly using Medfinder for Providers (medfinder.com/providers) and direct prescriptions there.
Submit the PA at the time of prescribing rather than waiting for a pharmacy rejection. Include documented migraine diagnosis, triptan trial failures or contraindications, and clinical rationale for intranasal delivery. Thorough documentation reduces back-and-forth with the payer.
Yes. There is no absolute contraindication to using Zavzpret (an acute CGRP receptor antagonist) alongside a preventive CGRP monoclonal antibody such as Aimovig, Ajovy, or Emgality. This combination is used clinically, though long-term safety data continues to evolve.
First, verify whether a peer-to-peer review or formal appeal is available. Strengthen the case with documented step therapy failures and clinical rationale. If the denial stands, consider the Pfizer Savings Card (commercial insurance) or Pfizer RxPathways (uninsured/underinsured). Alternatively, pivot to Ubrelvy or Nurtec ODT as therapeutic alternatives.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Ovide also looked for:
More about Ovide
30,909 have already found their meds with Medfinder.
Start your search today.





